Glutamine dipeptide supplementation improves clinical responses in patients with diabetic foot syndrome

• Autor(a) principal: Krupek, Tuane
• Data de Publicação: 2016
• Outros Autores: Silva, Maria Angélica Rafaini Covas Pereira da, Sant´Ana, Débora de Mello Gonçalves, Batista, Márcia Regina, Shimauti, Eliana Litsuko Tomimatsu, Sá-Nakanishi, Anacharis Babeto de, Comar, Jurandir Fernando, Schamber, Christiano Rodrigues, Moreschi Junior, Dorival, Bazotte, Roberto Barbosa
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Pharmaceutical Sciences
• Texto Completo: https://www.revistas.usp.br/bjps/article/view/128354

The effect of glutamine dipeptide (GDP) supplementation in patients with diabetic foot syndrome was evaluated. A total of 22 patients took part in the study. GDP was supplied in 10 g sachets, and was dissolved in water immediately before use, with ingestion once a day, after lunch or after dinner (20 g/day) over a period of 30 days. Quantification of foot insensitive areas, oxidative stress, blood cytokines, and biochemical, hematological and toxicological parameters was performed before and after GDP supplementation. We observed an increase in blood levels of interferon-α (P=0.023), interferon-γ (P=0.038), interleukin-4 (P=0.003), interleukin-6 (P=0.0025), interleukin-7 (P=0.028), interleukin-12 p40 (P=0.017), interleukin-13 (P=0.001), leukocytes (P=0.037), eosinophils (P=0.049), and typical lymphocytes (P